Gemmus Pharma Closes $3.3M Series B Funding To Develop Superior Flu Drug
SAN FRANCISCO--(BUSINESS WIRE)--Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targeted treatment for flu, today announced that it has closed on a Series B funding. The funding will be used to complete production and toxicology studies for an IND filing by the end of the year.
Help employers find you! Check out all the jobs and post your resume.